Activin receptor-like kinase 7 (ALK7), one of the type I transforming growth factor-b receptors, is expressed in various tissues, including the heart. However, the participation of ALK7 in the regulation of cardiac hypertrophy has not yet been studied. Here, we sought to determine the regulatory role and underlying mechanisms of ALK7 in cardiac hypertrophy.
Introduction
Cardiac hypertrophy is an adaptive response of the heart to altered conditions of haemodynamic overload caused by various physiological and pathological conditions. 1, 2 Cardiac hypertrophy may initially be a beneficial response that normalizes wall stress and maintains normal cardiac function; however, prolonged or excessive cardiac hypertrophy typically progresses to ventricular dilatation and eventually to heart failure. 3 Epidemiological studies have identified that cardiac hypertrophy is an important independent risk factor for the development of heart failure, arrhythmia, and sudden death, leading to increased cardiovascular morbidity and mortality. 4 Although multiple signalling mechanisms that control cardiomyocyte growth have been extensively studied in recent decades, the molecular mechanisms that mediate the development of cardiac hypertrophy and the transition to heart failure remain poorly understood. 5, 6 Thus, the delineation of hypertrophic mechanisms remains a priority within the field of cardiovascular biology and may lead to new strategies for the prevention or treatment of cardiovascular diseases. Activin receptor-like kinase 7 (ALK7), also known as ACVR1C, is one of the type I transforming growth factor-b receptors. 7, 8 ALK7 was first isolated from rat brain as an orphan receptor. 9 The human gene for ALK7 has been mapped to the genetic location of 2q24.1-q3. 10 Studies have demonstrated that ALK7 is present in human liver, intestine, adipose tissue, pancreas, and brain tissue. 10, 11 Notably, a recent study reported that ALK7 is expressed in rat cardiomyocytes.
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ALK7 comprises a transmembrane domain, a serine/threonine kinase domain, and a GS domain, which is located between the first two domains. The nodal, activin AB, and activin B ligands are specific for ALK7, and ActRII receptors are their primary ligand-binding receptors during signal transduction processes. 13, 14 Once ligands bind to ActRII, ALK7 is recruited to the ligand/ActRII complex, after which its GS domain becomes phosphorylated by ActRII kinases. Subsequently, ALK7 activates Smad-dependent and -independent pathways to regulate a variety of biological processes, including cell proliferation, differentiation, growth, development, and apoptosis. 15 -18 ALK7 has been demonstrated to be involved in various human diseases, including neuromuscular diseases, endocrine disorders, and cancers. 7, 8, 19 Moreover, a recent study suggested that ALK7 gene polymorphism is associated with cardiovascular remodelling. 20 In addition, previous studies have implicated ALK7 as a tumour suppressor gene in hepatomas and in breast and ovarian cancers. 16, 21, 22 Interestingly, increasing evidence has supported the involvement of tumour suppressors, such as Ras-association domain family 1 isoform A and A20, in modulating cardiac hypertrophy. 23 -25 These findings indicate that ALK7 may exert profound regulatory effects on cardiac pathology. However, to the best of our knowledge, the participation of ALK7 in the regulation of cardiac hypertrophy has not yet been studied. Here, we report that ALK7 expression is down-regulated in human hearts exhibiting hypertrophic cardiomyopathy (HCM) and in hypertrophic animal hearts. Using gain-of-function and loss-of-function approaches, we observed that chronic pressure overload-induced cardiac hypertrophy was aggravated in ALK7-knockout (KO) mice, but was blocked in ALK7-overexpressing mice. Mechanistically, we identified that the ALK7-dependent cardioprotective effect on cardiac hypertrophy was associated with the inhibition of MEK-ERK1/2 signalling. In fact, pharmaceutical inactivation of ERK1/2 limited the adverse effects of the ALK7-null mutation on aortic banding (AB)-induced cardiac remodelling. Our findings demonstrate for the first time that ALK7 is a novel negative regulator of pathological cardiac hypertrophy through the suppression of MEK-ERK1/2 signalling.
Methods

Reagents
Mouse anti-ALK7 antibody (AP 14606b) was obtained from Abgent, Inc. (San Diego, CA, USA). Human and rat anti-ALK7 antibody (HPA 011933) was obtained from Atlas Antibodies (Stockholm, Sweden). Antibodies against the following proteins were purchased from Santa Cruz Biotechnology (Dallas, TX, USA): b-MHC (sc53090) and ANP (sc20158). Antibodies to AKT (4691), phospho-AKT (4060), GSK3b (9315), phospho-GSK3b (9322), MEK1/2 (9122), phospho-MEK1/2 (9154), ERK1/2 (4695), phospho-ERK1/2 Thr202/Tyr204 (4370), JNK1/2 (9258), phospho-JNK1/2 (4668), P38 (9212), phospho-P38 (4511), Smad2 (3103), phospho-Smad2 (3108), Smad3 (9513), phospho-Smad3 (9520), and GAPDH (2118) were purchased from Cell Signaling Technology (Danvers, MA, USA). Antibody to phosphor-ERK2 (Thr-188, EP4101) was purchased from the ECM Biosciences. BCA protein assay kits were purchased from Pierce (Rockford, IL, USA). Fetal calf serum (FCS) was ordered from HyClone (Waltham, MA, USA). Cell culture reagents and other reagents were purchased from Sigma (St. Louis, MO, USA).
Human heart samples
All procedures involving human tissue samples were approved by the Human Research Ethics Committee of the Renmin Hospital of Wuhan University, Wuhan, China. This study conformed to the principles outlined in the Declaration of Helsinki. Informed consent was obtained from the families of prospective heart donors. Samples of failing human hearts were collected from the left ventricles of patients with HCM undergoing heart transplants. 2 Control samples were obtained from the left ventricles of healthy heart donors who died in accidents, but whose hearts were not suitable for transplantation for non-cardiac reasons. 2 
Study animals
All experiments involving animals were approved by the Animal Care and Use Committee of Renmin Hospital at Wuhan University and confirmed the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (the 8th Edition, NRC 2011). All of the animals were housed in an environment with controlled light cycles (12 h light/12 h dark), temperature, and humidity; food and water were provided ad libitum. All of the animal experiments were performed by an experimenter who was blinded to the animals' genotypes.
2.4 ALK7-KO and cardiac-specific ALK7-transgenic mice ALK7 global KO mice (B6.129P2-Acvr1c tm1Cfi/Kctt , EM:02574) were ordered from the European Mouse Mutant Archive (Neuherberg/Munich, Germany). The obtained ALK7-KO mice were confirmed using western blot analyses. Cardiac-specific ALK7-transgenic (TG) mice were generated by microinjection of full-length mouse ALK7 cDNA under transcriptional control of the a-myosin heavy chain (MHC) promoter into fertilized embryos (C57BL/6J background). Successful insertion in the ALK7-TG mice was confirmed by genotyping using PCR; tail genomic DNA was used as the template with the following primers: forward: 5 ′ -ATC TCCCCCATAAGAGTTTGAGTC-3 ′ and reverse: 5 ′ -GCTTCCTCCAC GTTGTGTCT-3 ′ . Four independent lines were obtained for ALK7-TG mice, and each showed a similar phenotype.
AB procedure
Male ALK7-KO and C57BL/6J (wild-type, WT) littermate control as well as ALK7-TG and non-TG (NTG, C57BL/6J background) littermate control mice aged 8 -10 weeks (24 -27 g) were subjected to AB or a sham operation, as described previously. 2 Briefly, mice were anaesthetized intraperitoneally using sodium pentobarbital (50 mg/kg), and the adequacy of anaesthesia was monitored during the surgical procedures using lack of the pedal withdrawal reflex, slow constant breathing, and no response to surgical manipulation. Buprenorphine (0.1 mg/kg, s.c.) was administered for postoperative analgesia. The left chest of each mouse was opened to identify the thoracic aorta by blunting dissection at the second intercostal space, which was tied against a 26-G needle on the thoracic aorta with a 7-0 silk suture. After ligation, the needle was quickly removed, and the thoracic cavity was closed. In addition, Doppler analysis was performed to ensure that the aorta had been adequately constricted. At the indicated time point after surgery, mice were killed using an overdose of sodium pentobarbital (200 mg/kg), injected intraperitoneally. The heart weight (HW)/body weight (BW) (mg/g), HW/tibia length (TL) (mg/mm), and lung weight (LW)/BW (mg/g) ratios of the mice were measured in different groups.
Treatment with MEK1/2 inhibitor (U0126)
U0126, a highly selective inhibitor of MAPK kinase (MEK) 1/2, was purchased from Cell Signaling Technology (Beverly, MA, USA), dissolved in dimethyl sulfoxide (DMSO), and administered at a constant volume of 1 mL per 100 g of BW by an intraperitoneal injection every 3 days (1 mg/ kg/3 days). 26 
Adenoviral vectors and cultured neonatal rat cardiac myocytes
To overexpress ALK7, we used replication-defective adenoviral vectors encompassing the entire coding region of the ALK7 gene under the control of the CMV promoter, and a similar adenoviral vector expressing green fluorescent protein (GFP) was used as a control. To knockdown ALK7 expression, three SureSilencing mouse shALK7 constructs were obtained from ALK7 ameliorates pathological cardiac hypertrophy SABiosciences (KR44935G); the construct that produced the most significant reduction in ALK7 levels was selected for further experiments (designated AdshALK7). AdshRNA was used as a non-targeting control.
Neonatal rat cardiac myocytes (NRCMs) were prepared from the ventricles of 1-to 3-day-old Sprague-Dawley rats, as described previously. 2 Briefly, Sprague-Dawley rats, which were sacrificed by swift decapitation according to the Guide for the Care and Use of Laboratory Animals published by the United States National Institutes of Health, that were 1 -2 days of age were euthanized, and cardiectomies were performed. We infected cardiomyocytes with AdALK7, Ad-GFP, AdshALK7, or AdshRNA at a multiplicity of infection of 100, resulting in transgene expression without toxicity in 95 -100% of the cells. For cell infection, cardiomyocytes were cultured at a density of 1 × 10 6 cells/well in six-well plates and exposed to 2 × 10 8 pfu each of virus in 1 mL of DMEM/F12 medium containing 20% FCS, BrdU (0.1 mM), and penicillin/streptomycin without serum for 24 h. The cells were then washed and incubated in serum-containing medium for 48 h in the presence or absence of 1 mM Ang II.
Western blot analysis
Proteins were obtained from heart tissues and cultured NRCMs using RIPA lysis buffer (50 mM Tris -HCl, 1 mM PMSF, Complete, Phosstop, 50 mM NaF, 1 mM Na 3 VO 4 ). Immunoblotting was performed as previously described. 2 The protein expression levels were quantified and normalized to a GAPDH loading control.
Real-time quantitative PCR
Total RNA was extracted from the frozen heart tissues and cultured NRCMs using TRIzol reagent (7950567275, Roche). cDNA was synthesized from 2 mg of RNA obtained from each sample using the Transcriptor First Strand cDNA Synthesis Kit (Roche, 04896866001). To examine the relative mRNA expression levels of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), b-MHC, connective tissue growth factor (CTGF), collagen I, and collagen III, quantitative real-time PCR reactions were performed in 20 mL volumes (Light Cycler 480 SYBR Green I Master, 04887352001, Roche) using the LightCycler w 480 Real-time PCR system (Roche) according to the manufacturer's instructions. Data were normalized based on the GAPDH signal and expressed as relative mRNA levels.
Histological analysis and immunofluorescence staining
A histological analysis of the hearts was carried out as described previously. 2 Briefly, mice were anaesthetized intraperitoneally using sodium pentobarbital (100 mg/kg), and were sacrificed by swift decapitation according to the Guide for the Care and Use of Laboratory Animals published by the United States National Institutes of Health. Hearts were arrested with 1 M KCl and fixed in 10% formalin, embedded in paraffin, sectioned into 5-mm slices, and stained with haematoxylin -eosin (H&E) for histopathology or with Picrosirius Red (PSR) to examine collagen deposition; after staining, the sections were visualized using LM. To visualize cellular membranes and determine the cross-sectional area (CSA) of myocytes, Wheat germ agglutinin (WGA, Sigma, St. Louis, MO, USA) was used. A single myocyte was measured using a quantitative digital image analysis system (Image-Pro Plus 6.0). Based on the PSR-stained sections, the left ventricular (LV) collagen volume fraction was calculated as the area stained by PSR divided by the total area.
For the cultured cardiomyocyte staining experiments, cells were first infected with various adenoviruses for 24 h and subsequently stimulated with PBS or with 1 mM Ang II for 48 h. Then, the cells were fixed with 3.7% formaldehyde in PBS, permeabilized using 0.1% Triton X-100 in PBS, and stained with a-actinin at a dilution of 1 : 100 using standard IF staining techniques. To stain nuclei, 4,6-diamidino-2-phenylindole (DAPI, Sigma) was applied. Images were acquired using a fluorescence microscope (OLYMPUS DX51) and the DP2-BSW software (version 2.2), and the images were analysed using the Image Pro Plus software (version 6.0). The images were quantitatively analysed by technicians in a blinded fashion.
Echocardiography and haemodynamic measurements
Echocardiography was performed using a MyLab 30CV ultrasound instrument (Biosound Esaote, Inc., Italy) equipped with a 10-MHz linear array ultrasound transducer; invasive haemodynamic measurements were performed using a microtip catheter transducer (SPR-839, Millar Instruments, Houston, TX, USA), which was inserted into the carotid artery and advanced into the LV. Both types of measurements were performed on anaesthetized (1.5 -2% isoflurane) mice, as previously described. 2,27 -30 The LV end-systolic diameter (LVESD) and LV end-diastolic diameter (LVEDD) were measured from the 2D short-axis under M-mode tracings at the level of the papillary muscle. LV mass and functional parameters, such as the percentage of fractional shortening (FS, %), ejection fraction (EF, %), and maximum and minimum values of dp/dt, were calculated using the above primary measurements and the appropriate accompanying software.
Statistical analysis
Data are represented as means + SD. The two-tailed Student's t-test was used to compare the means of data acquired from human samples, and oneway ANOVA with LSD (assuming equal variances) or Tamhane's T2 (without the assumption of equal variances) test was used to compare the means of b-MHC, MYH7, and ALK7 expression levels in WT mice, and all other data were statistical analysis with two-way ANOVA with general linear model procedures using a univariate approach. P-values that were ,0.05 were regarded as statistically significant.
Results
The expression of ALK7 is down-regulated in HCM human hearts and in AB-operated mouse hearts
To explore the correlation between ALK7 and cardiac hypertrophy, we first examined ALK7 expression in diseased hearts. Western blotting revealed that ALK7 protein expression levels were significantly lower in heart samples collected from human patients experiencing HCM than in samples from donor hearts ( Figure 1A and B) . The lower ALK7 expression in HCM hearts was accompanied by up-regulation of the expression of cardiac hypertrophic markers, including ANP and myosin heavy chain 7 (MYH7; Figure 1A and B). Furthermore, in an experimental mouse model exhibiting AB-induced cardiac hypertrophy (as shown by elevated ANP and MYH7 levels, Figure 1C and D), we observed that ALK7 levels were expressed at progressively lower levels in mouse hearts after AB than in sham-operated hearts ( Figure 1C and D) . These results suggest that ALK7 may be involved in the development of cardiac hypertrophy.
ALK7 prevents cardiomyocyte hypertrophy in vitro
To identify whether ALK7 regulates the progression of cardiac hypertrophy, we first performed loss-and gain-of-function studies using primary cultured NRCMs, which is a well-controlled experimental setting. Primary cultured NRCMs were infected with either AdshALK7 to knockdown ALK7 or with AdALK7 to overexpress ALK7 (Figure 2A) , and then treated with either Ang II (1 mM) or PBS as a control for 48 h; after treatment, the cells were immunostained with a-actinin to measure the size of the cells. Under basal conditions (PBS treatment), neither AdshALK7 nor AdALK7 affected the size of NRCMs in comparison with the control AdshRNA and AdGFP cells. However, following Ang II stimulation, AdshALK7 infection remarkably promoted Ang II-induced cardiomyocyte hypertrophy, whereas AdALK7 significantly decreased cell hypertrophy, as evaluated by the cardiomyocyte cell surface area ( Figure 2B-D) . Accordingly, the induction of hypertrophic hallmarks (ANP, BNP, and b-MHC) was aggravated by ALK7-knockdown, but was suppressed by ALK7 overexpression ( Figure 2E and F ) . These data indicate that ALK7 acts as a negative regulator of cardiac hypertrophy.
ALK7 deficiency aggravates pressure overload-induced cardiac hypertrophy
To define the anti-hypertrophic effects of ALK7 in vivo, we then performed AB surgery on ALK7 global KO (ALK7 2/ 2 ) mice in whom ALK7 is absent in all tissues, including the heart ( Figure 3A) . At baseline, the ALK7 2/2 mice exhibited a normal cardiac phenotype (data not shown). However, after a 4-week course of AB, the ALK7 2/2 mice exhibited a remarkable deterioration of cardiac hypertrophy compared with ALK7 +/+ (WT) mice, as evidenced by higher ratios of HW/BW, LW/BW, and HW/TL ( Figure 3B and Supplementary material online, Figure S1A and B) . Both H&E and WGA staining consistently revealed that the cardiomyocyte CSA was higher in ALK7 2/2 mice than in ALK7
+/+ mice after 4 weeks of AB ( Figure 3C and D) . Consistent with these data, the expression levels of hypertrophic markers (ANP, BNP, and b-MHC) were much higher in AB-treated ALK7 2/2 hearts than in control hearts ( Figure 3E) . Furthermore, ALK7 2/2 mice exhibited deteriorations in cardiac dilation and dysfunction, as demonstrated by the results of echocardiographic and haemodynamic measurements, including LVEDD, LVESD, FS, LVEF, and the maximum and minimum rates of pressure increase in LV isovolumetric contractions (dp/dt max and dp/dt min, respectively; Figure 3F -H and Supplementary material online, Figure S1C -E).
Given that fibrosis is a classical feature of cardiac hypertrophy, we also assessed the effect of ALK7 deficiency on AB-triggered cardiac fibrosis. Heart sections were stained with PSR to assess the extent of fibrosis in the heart. Our results demonstrated that cardiac fibrosis was more prominent in AB-operated ALK7 2/ 2 mice than in AB-treated ALK7 +/+ mice ( Figure 3I ). Furthermore, we quantified the extent of cardiac fibrosis using the LV collagen volume and the expression of fibrotic markers (collagen I, collagen III, and CTGF), and found that the pressure overload triggered a much greater fibrotic response in ALK7 2/2 hearts than in ALK7 +/+ hearts ( Figure 3J and K ). Collectively, these loss-of-function data indicate that ALK7 deficiency aggravates pressure overload-induced cardiac hypertrophy.
ALK7 overexpression mitigates pathological cardiac hypertrophy
We subsequently sought to examine whether elevated levels of ALK7 in the heart attenuate cardiac hypertrophy. To address this hypothesis, we generated a TG mouse model with cardiac-specific ALK7 expression using the a-MHC promoter. Four lines of ALK7-TG mice were created, and these lines were verified using western blotting ( Figure 4A) . At baseline, all ALK7-TG mice were healthy and exhibited normal cardiac morphology and contractile function (data not shown).
We then selected the highest-expressing ALK7 line (TG4) for further ALK7 ameliorates pathological cardiac hypertrophy experiments. ALK7-TG mice and their WT littermates (referred to as 'NTG' hereafter) were subjected to AB surgery or sham operation for 4 weeks. As expected, the HW/BW, LW/BW, and HW/TL ratios were significantly lower in AB-treated TG hearts than in AB-treated NTG hearts ( Figure 4B and Supplementary material online, Figure S2A and B). In addition, the results of a histological analysis indicated that the CSA of the cardiomyocytes was dramatically lower in AB-operated TG mice than in the NTGs ( Figure 4C and D) . Consistent with these data, hearts from TG mice showed lower hypertrophic marker induction (ANP, BNP, and b-MHC) after 4 weeks of AB compared with controls ( Figure 4E) . Accordingly, ALK7 overexpression significantly inhibited AB-triggered cardiac dilation and dysfunction, as determined by echocardiographic and haemodynamic measurements ( Figure 4F -H and Supplementary material online, Figure S2C -E). We also evaluated the effect of ALK7 overexpression on AB-induced cardiac fibrosis. Both the histological analysis and fibrotic marker analyses consistently demonstrated a lower fibrotic response in AB-operated ALK7-TG mice than in AB-treated NTG mice ( Figure 4I -K ) . Taken together, these gain-of-function data indicate that ALK7 overexpression mitigates cardiac hypertrophy in response to chronic pressure overload.
ALK7 modulates the MEK -ERK1/2 and Smad signalling pathways in the heart
The aforementioned results suggest that ALK7 might play a protective role against cardiac hypertrophy. However, the underlying mechanism by which ALK7 exerts its anti-hypertrophic response is unclear. Therefore, we first examined the activation state of the AKT signalling cascade, a pathway associated with cardiac hypertrophy. No differences were observed in the activation of AKT and its downstream target GSK3b between ALK7 2/ 2 and ALK7 +/ + hearts or between ALK7-TG mice and NTG mice after AB (see Supplementary material online, Figure S3A and B). Because MAPK signalling pathways in the heart are activated by various hypertrophic stresses, we investigated the possible involvement of MAPK pathways in ALK7-mediated cardioprotective effects. Western blot analyses demonstrated that AB significantly increased the levels of phosphorylated MEK1/2, ERK1/2, JNK1/2, and p38 in both ALK7 2/2 and ALK7 +/+ hearts after 4 weeks of AB ( Figure 5A) . However, the degree of MEK1/2 and ERK1/2 activation was significantly greater in ALK7 2/ 2 hearts than in ALK7
hearts, although similar levels of JNK1/2 and p38activation were observed in these groups ( Figure 5A) . Similarly, in gain-of-function experiments, we observed that the AB-induced activation of MEK1/2 and ERK1/2 was almost completely blocked in ALK7-TG hearts ( Figure 5B ). To confirm these findings and exclude potential in vivo compensatory mechanisms, we further examined the effect of ALK7 on MEK-ERK1/2 signalling using cultured NRCMs. NRCMs were infected with AdshALK7 to knockdown ALK7 or with AdALK7 to overexpress ALK7, and then treated with 1 mM Ang II for 48 h. In accordance with the in vivo findings, Ang II-induced activation of MEK1/2 and ERK1/2 ALK7 ameliorates pathological cardiac hypertrophy was enhanced in ALK7-knockdown cells but attenuated in ALK7-overexpressing cells (see Supplementary material online, Figure  S3C and D).
To further elucidate the molecular mechanisms underlying the antifibrotic effects of ALK7, we assessed the regulatory role of ALK7 on Smad cascade activation, which is involved in the pathological process of cardiac fibrosis. Western blotting results showed that AB induced a significant increase in Smad 2/3 phosphorylation, which was enhanced in ALK7 2/ 2 mice and attenuated in ALK7-TG mice ( Figure 5C and D) . To confirm these in vivo findings, we next examined the effects of ALK7 on Smad signalling in vitro. Cardiac fibroblasts were subjected to either AdshALK7-mediated ALK7-knockdown or Ad ALK7-mediated ALK7 overexpression, followed by treatment with 1 mM Ang II for 48 h. As expected, Ang II-induced Smad 2/3 phosphorylation was markedly increased by AdshALK7, but dramatically attenuated by AdALK7 (see Supplementary material online, Figure S3E and F). These data suggest that ALK7-elicited cardioprotective effects are associated with the inhibition of the MEK -ERK1/2 and Smad2/3 signalling cascades in hearts subjected to pressure overload.
3.6 Inactivation of MEK-ERK1/2 signalling rescues the adverse effect of ALK7 deficiency on pressure overload-induced cardiac remodelling
To test whether the abnormalities exhibited in AB-treated ALK7-deficient mice could be reversed by pre-inhibition of MEK -ERK1/2 signalling, we treated ALK7 2/ 2 and ALK7 +/ + mice with a specific MEK inhibitor, U0126, or with PBS followed by 4 weeks of AB. Both the gravimetric data and histological examination demonstrated that U0126 treatment significantly reversed the deteriorative effects of ALK7 deficiency on the hypertrophic and fibrotic response 4 weeks after AB compared with PBS-treated controls ( Figure 6A -D and Supplementary material online, Figure S4A and B). Meanwhile, U0126 treatment also markedly limited AB-induced cardiac dilation and dysfunction compared with PBS-treated groups, as measured using echocardiography and haemodynamic measurements ( Figure 6E -G and Supplementary material online, Figure S4C -E). These data suggest that ALK7-mediated cardioprotective effects are largely dependent on the inhibition of MEK-ERK1/2 signalling.
Discussion
In the present study, we utilized both gain-and loss-of-function approaches to determine the role of ALK7 in pathological cardiac hypertrophy. We found that ALK7 expression was significantly reduced in failing hearts. More importantly, we observed for the first time that the absence of ALK7 resulted in detrimental effects on the development of pathological cardiac hypertrophy; conversely, ALK7 overexpression in the heart limited chronic pressure overload-induced cardiac remodelling. These novel findings clearly suggest that endogenous ALK7 might play a crucial role in modulating the transition of cardiac hypertrophy to heart failure. Thus, ALK7 elevation may serve as a new therapeutic strategy for the treatment of pathological cardiac hypertrophy. However, given that ALK7 is present in various tissues, regulates a variety of biological processes, and is involved in various human diseases, the systematic effect of pathological cardiac hypertrophy treatment targeting ALK7 needs to be further determined. The present study demonstrated that loss of ALK7 promotes AB-induced cardiac hypertrophy, whereas ALK7 overexpression in the heart results in the opposite phenotype. These results indicate that ALK7 plays a critical role in protecting the heart against maladaptive responses to stress, and these findings contrast with previous findings regarding another ALK protein, ALK5. In fact, the targeted inhibition of ALK5 signalling attenuates cardiac remodelling and dysfunction in an experimental rat model of myocardial infarction. 27 In addition, the inhibition of ALK5 signalling prevents the development and progression of pulmonary hypertension. 28 Therefore, ALK proteins may exert their effects through different molecular mechanisms due to their structural heterogeneity and their differential ligand specificities. Additionally, we observed that cardiac ALK7 expression was decreased not only in AB-treated mouse hearts but also in the hearts of human HCM patients. These findings suggest that ALK7 may be involved in the development of pathological cardiac hypertrophy. However, the mechanism that causes alterations in ALK7 expression during cardiac remodelling is not known. Further research is needed to investigate the regulatory mechanism of ALK7 expression during the development of cardiac remodelling. Mechanistically, the cardioprotective effect of ALK7 on pathological cardiac remodelling might be largely exerted by inhibiting MEK-ERK1/2 signalling. It is generally accepted that biomechanical stress can trigger a variety of signal transduction molecules and pathways that regulate the hypertrophic growth of cardiac myocytes. 5, 6 Numerous studies have demonstrated that both the MAPK signalling pathway is often activated in response to extracellular stress, and both of these pathways have been shown to contribute to cardiac remodelling and heart failure. 5, 6 In mammals, there are three major MAPK signalling cascades, the ERK, JNK, and p38 MAPK cascades. Activation of the MAPK cascades leads to phosphorylation of intracellular numerous transcription factors, resulting in the reprogramming of cardiac gene expression. The precise role that MEK1-ERK1/2 plays in the regulation of cardiac hypertrophy is an area of ongoing debate. A number of previous studies showed that genetic inhibition of ERK1/2 signalling in the heart promotes cardiac dilation by enhancing growth in myocyte length. 29 -31 However, it has been shown that hypertrophic stimuli, e.g. G protein-coupled receptor agonists or biomechanical stress, activated ERK1/2 and thereby induced hypertrophic responses. 32, 33 Constitutive activation of ERK1/2 signalling in the heart through expression of activated MEK1 induced LV hypertrophy. 34 The attenuation of hypertrophic responses by the use of pharmacological inhibitors of MEK1/2, dominant-negative ALK7 ameliorates pathological cardiac hypertrophy MEK1, and antisense oligonucleotides against ERK1/2 further supports the important role of the MEK -ERK1/2 signalling in cardiac hypertrophy. 5, 35, 36 More recently, a novel autophosphorylation site of ERK1/2 at Thr188 was identified. This autophosphorylation occurs in response to hypertrophic stimuli and appears to facilitate ERK1/2 activity towards nuclear targets that are important for the induction of cardiac hypertrophy. 37 Our previous study also showed that inhibition of MEK1 -ERK1/2 signalling protected the hearts against cardiac hypertrophy. 26 In the present study, we found that activation of both MEK1/2 and ERK1/2 was enhanced by the loss of ALK7, but was blocked by cardiac ALK7 overexpression in response to chronic pressure overload. However, ALK7 did not affect the phosphorylation of p38, JNK1/2, AKT, or GSK3b. More importantly, the ALK7-null-induced pro-hypertrophic effects were rescued by a MEK -ERK1/2 inhibitor, indicating that the MEK -ERK1/2 signalling pathway is critically involved in the anti-hypertrophic effects of ALK7. These findings support the notion that ALK7 negatively regulates pathological cardiac hypertrophy largely by inhibiting the MEK -ERK1/2 signalling axis. Furthermore, we examined the phosphorylated level of Thr188 ERK1/2 in the hearts of ALK7 +/+ and ALK7 2/2 mice in response to pressure overload. Western blot analyses showed that AB significantly increased the phosphorylated level of Thr188 ERK1/2. However, the degree of Thr188 ERK1/2 activation was similar in ALK7 2/2 hearts and ALK7 +/+ hearts after 4 weeks of AB (see Supplementary material online, Figure S5 ). These results suggest that the antihypertrophic effect of ALK7 is independent of the inhibition of Thr188 ERK1/2 phosphorylation. Pathological cardiac hypertrophy is typically accompanied by interstitial and perivascular fibrosis. 2 The present study revealed for the first time that ALK7 blocks cardiac fibrosis. Previous studies suggest that the Smad signalling pathway is closely associated with cardiac fibrosis. 26 Inhibition of the Smad signalling pathway has been predicted to suppress cardiac fibrosis. In an attempt to elucidate the mechanisms underlying the inhibitory effect of ALK7 on cardiac fibrosis, we examined the status of Smad2/3 signalling. Interestingly, our data indicate that ALK7 mitigates Smad 2/3 phosphorylation in both hypertrophied hearts and in cultured cardiac fibroblasts, thus inhibiting cardiac fibrosis. ALK7 has been shown to activate the Smad transcriptional regulators, Smad2 and Smad 3. 12 However, recent studies suggest that Smad signalling can be regulated by the MEK-ERK1/2 signalling pathway. 26, 38, 39 Blocking MEK-ERK1/2 activation resulted in significant inhibition of collagen synthesis and Smad 2/3 signalling, whereas activation of MEK-ERK1/2 led to the up-regulation of collagen synthesis and Smad 2/3 signalling. In fact, we found that pharmacological inhibition of MEK-ERK1/2 signalling by U0126 markedly reversed the aggravated fibrosis displayed in ALK7-KO mice in vivo. Furthermore, we found that ALK7-KO led to a significant increase in Smad 2/3 phosphorylation after 4 weeks of AB, which was blocked by U0126 treatment (see Supplementary material online, Figure S6 ). These results indicate that ALK7 may attenuate cardiac fibrosis by blocking MEK-ERK1/2 signalling and subsequently inhibiting Smad 2/3 signalling. Further research is necessary to elucidate the precise cross-talk mechanism between MEK-ERK1/2 signalling and Smad signalling. Cardiac myocyte apoptosis is also a critical factor during the transition from compensatory cardiac hypertrophy to heart failure in response to pressure overload. Previous studies have demonstrated that the activation of ALK7 resulted in increased apoptosis in hepatoma cells, pancreatic b-cells, and human trophoblast cells. 16, 17, 40 However, the present study showed that there was no significant difference in myocyte apoptosis between ALK7 2/ 2 mice and ALK7 +/ + mice, Statistical results for dp/dt max in the indicated groups (n ¼ 5 -6). ALK7 +/+ /U0126 vs. ALK7 +/+ /saline, P , 0.05; ALK7 2/2 /U0126 vs. ALK7 2/2 /saline, P , 0.05. n indicates the number of mice in each experimental group. The data represent as the mean + SD. Statistical analysis was carried out by two-way ANOVA with general linear model procedures using a univariate approach.
ALK7 ameliorates pathological cardiac hypertrophy ALK7-TG mice and NTG mice, or ALK7 +/+ and ALK7 2/2 mice treated with U0126 after 4 weeks of AB (see Supplementary material online, Figure 7 ). These data indicate that the cardioprotective effect of ALK7 on cardiac remodelling is independent of apoptosis.
In conclusion, we have revealed a novel role for ALK7 in regulating cardiac remodelling. Mechanistically, ALK7 serves as a protective regulator during the development of pathological cardiac hypertrophy largely by inhibiting the MEK -ERK1/2 signalling pathway. Our observations provide new insights into the mechanisms of pathological cardiac hypertrophy and may have significant implications for the development of novel strategies for the treatment of pathological cardiac remodelling.
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